This message was sent to ##Email##
|
|
|
ACS CANCER PROGRAMS UPDATES |
A group of 25 cancer registrars from accredited institutions has been awarded scholarships to attend the American College of Surgeons (ACS) 2019 Quality and Safety Conference this week in Washington, DC. ACS Cancer Programs awarded each of the registrars a $1,000 scholarship to help cover registration, travel and hotel costs. Those attending will have the opportunity to attend educational sessions, meet Cancer Program members and staff and network with colleagues from around the country.
CAnswer Forum is an interactive bulletin board where Commission on Cancer (CoC) constituents can ask questions, search topics and connect with the latest CoC news and activities. The bulletin board is designed as an open forum for networking and discussion. Users will find information on a wide variety of topics, including American Joint Committee on Cancer (AJCC) TNM Staging, Cancer Program standards, Standards for Oncology Registry (STORE), National Cancer Database (NCDB), National Accreditation Program for Breast Centers (NAPBC) and the National Accreditation Program for Rectal Cancer (NAPRC).
CAnswer Forum LIVE, a series of 60-minute webinars scheduled throughout the year, is open to staff at current and prospective CoC, NAPBC and NAPRC programs. Upcoming webinars are scheduled for Sept. 25 and Dec. 11. Go to the CAnswer Forum LIVE website to learn more and to access recordings of previous broadcasts.
|
SERVICE SHOWCASE | Advertisement
|
 |
|
Doctors Without Borders/Médecins Sans Frontières (MSF) is actively recruiting general and trauma surgeons with experience in emergency obstetrics for international missions in developing countries. Learn more
|
|
The ACS Clinical Research Program (ACS CRP) is offering a limited number of scholarships to surgery residents who are interested in attending the didactic course “Designing and Running a Prospective Surgical Clinical Trial” at the upcoming ACS Clinical Congress in San Francisco, CA. This course is being held on Sunday, October 27 from 8:30 am PT to 4 pm PT at the Moscone Center. The course is designed to teach the methodology of design and implementation of a clinical trial for surgeons interested in developing and leading a prospective trial.
This scholarship award of $290 is available to Resident and Associate Society (RAS) members and must be used to cover the registration cost for the didactic course. This award would be paid following confirmation of course attendance. Applications are due by July 31, 2019. Additional information, including application requirements, can be found on the ACS website.
Surgeons who evaluate and treat cancer patients at CoC-accredited cancer programs who are not board certified must complete 12 cancer-focused CME Credit hours each calendar year.
Thirty-eight Clinical Congress 2019 sessions have been identified and designated as Credit to Address ACS Cancer Accreditation Requirements. To see a list of these sessions, visit the Find a Session web page and use the Credit to Address Accreditation/Verification Requirements search filter. Individuals may elect to claim the Credit to Address ACS Accreditation/Verification Requirements, which will then be documented on the CME Certificate and Clinical Congress transcript.
In addition to meeting accreditation CME requirements, attendees will be able to complete many state CME requirements and MOC/Continuous Certification CME. Register for Clinical Congress 2019 today!
If you have questions or would like additional information, please contact Liz McAllister at emcallister@facs.org or 312-202-5122.
|
|
|
|
Advertisement
|
|
|
|
|
|
|
|
NAPBC is hosting a workshop, Pursuing Excellence through NAPBC Accreditation, in Denver, CO, on Friday, September 20, 2019, at the Hilton Denver City Center. Registration is now open for the workshop, which will focus on how programs can best achieve compliance. Be sure to register before August 9 to receive the early bird rate of $395. To learn more, click here.
|
SPONSORED CONTENT | Advertisement
|
Promoted by
|
|
|
 |
Surgeons on the breast care team at NAPBC-accredited centers must complete 2 CME Credit hours in the area of breast disease annually. Physicians providing genetic counseling and evaluation must complete an additional 2 genetics-related CME Credit hours each year.
Fourteen Clinical Congress 2019 sessions have been identified and designated as Credit to Address ACS Breast Accreditation Requirements. To see a list of these sessions, visit the Find a Session web page and use the Credit to Address Accreditation/Verification Requirements search filter. Individuals may elect to claim the Credit to Address ACS Accreditation/Verification Requirements, which will then be documented on the CME Certificate and Clinical Congress transcript.
In addition to meeting accreditation CME requirements, attendees will be able to complete many state CME requirements and MOC/Continuous Certification CME. Register for Clinical Congress 2019 today!
If you have questions or would like additional information, please contact Liz McAllister at emcallister@facs.org or 312-202-5122.
 |
|
VTI’s Remotely Operated Suction Irrigation System (or “ROSI”) presents a new paradigm in suction and irrigation for robot-assisted procedures. The ROSI system gives the console surgeon complete control of suction and irrigation capabilities.
|
|
The Rapid Quality Reporting System (RQRS) is currently accepting cases in NAACCR v18 and v16 format. The quality measure specifications for the RQRS breast and colon sites have been updated on the website. The RQRS breast and colon quality measure algorithms will perform eligibility checks for cases staged using the AJCC 8th edition beginning with the 2018 diagnoses and will use the new site-specific data item codes when applicable. Cases diagnosed before 2018 will continue to be evaluated using the AJCC 7th edition staging system and will use the existing site-specific factors where applicable. The use of the v18 radiation data items will be allowed for all cases. CP3R will start processing cases diagnosed in 2018 in 2020; the remaining CP3R quality measures will be updated then.
RQRS quality measure changes or updates:
- MAC: When neo-adjuvant treatment is administered, and ER/PR status is negative, chemotherapy will be evaluated regardless of tumor size.
HEALTH CARE NEWS AND UPDATES |
Medscape
New cancer drugs and cancer diagnostic tests have been added to the World Health Organization's (WHO's) lists of essential medicines and essential diagnostic tests.
"Around the world, more than 150 countries use WHO's essential medicines list to guide decisions about which medicines represent the best value for money, based on evidence and health impact," said WHO Director-General Tedros Adhanom Ghebreyesus, PhD.
READ MORE
Medical News Today
In a recent study, researchers trained an algorithm to differentiate between malignant and benign lesions in scans of breast tissue. With cancer, the key to successful treatment is catching it early.
As it stands, doctors have access to high quality imaging, and skilled radiologists can spot the telltale signs of abnormal growth.
READ MORE
Oncology Nurse Advisor
Urine-derived extracellular vesicle RNA can provide diagnostic information for aggressive prostate cancer prior to biopsy as well as prognostic information for men under active surveillance for prostate cancer, according to a study published online June 25 in BJU International.
READ MORE
Stat News
The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone, but that the benefit was still only a few months for two forms of cancer, study sponsor Neon Therapeutics reported recently.
READ MORE
Medical News Today
High-grade serous ovarian cancer is the most common form of ovarian cancer. In most people, the cancer develops resistance to chemotherapy and returns. Now, a new study raises hopes for a different kind of treatment. Working with cell cultures, researchers found that an enzyme they call isocitrate dehydrogenase 1 (IDH1) encourages the proliferation of high-grade serous ovarian cancer cells.
READ MORE
New Scientist
Cancer treatment is becoming more precise through personalised therapies. A survey of more than 1000 people with cancer found that over a third had received genetically targeted drug treatments or immunotherapy.
“Going back 20 years, the vast majority of cancer patients who had treatment for their disease were on traditional, one-size-fits-all chemotherapy – with targeted drugs practically unknown, and immunotherapy the stuff of science fiction,” said Rajesh Chopra at the Institute of Cancer Research (ICR) in London, in a statement.
READ MORE
IMPORTANT DATES AND DEADLINES |
|
|
|
| The Brief
Connect with AJCC

Connect with CoC

Connect with NAPBC

Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit Victoria Scott, Content Editor, 289-695-5367 | Contribute news
Disclaimer: The Brief is a digest of news selected for the American College of Surgeons Cancer Programs from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The American College of Surgeons and Cancer Programs do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the authors and not of the American College of Surgeons, and the Cancer Programs.
American College of Surgeons 633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
 7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|